Genprex to Present at the MoneyShow June Virtual Event
June 08 2020 - 08:17AM
Business Wire
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company developing potentially
life-changing technologies for patients with cancer and diabetes,
announced that the Company will present at the MoneyShow June
Virtual Event on Wednesday, June 10, 2020 at 12:50 p.m. EDT.
Mr. Rodney Varner, Genprex’s Chairman and Chief Executive
Officer, will deliver an overview of the Company and provide
updates on its product pipeline, including its lead drug candidate,
Oncoprex™ immunogene therapy, which received Fast Track Designation
from the Food and Drug Administration for its combination therapy
with AstraZeneca’s Tagrisso®. He will also provide an overview of
the Company’s in-licensing of a preclinical diabetes gene therapy
candidate that has the potential to cure Type 1 and Type 2
diabetes.
Event: MoneyShow June Virtual Event
Presentation Date: Wednesday, June 10, 2020
Presentation Time: 12:50 p.m. – 1:20 p.m. EDT
Free Live Webcast Link: https://bit.ly/2zPIfiV
Registration to watch Mr. Varner’s live presentation is free.
The live presentation will also be post-produced and made available
on MoneyShow.com and MoneyShow’s Youtube channel for on-demand
viewing.
About MoneyShow
MoneyShow has been providing self-directed investors and traders
with market analysis, investing tools, extensive educations,
trading strategies, and portfolio advice from financial experts for
nearly 40 years. Given the current climate and COVID-19 impact,
MoneyShow has now also gone virtual in its efforts to maintain its
outreach to investors. Investors can sign-up for free to join the
100,000+ other members ready to hear in-depth analysis and specific
strategies for stocks, bonds, ETFs, commodities, options, futures,
forex, and more. For more information about MoneyShow, please visit
www.moneyshow.com/online-events.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with
cancer and diabetes. Genprex’s technologies are designed to
administer disease-fighting genes to provide new treatment options
for large patient populations with cancer and diabetes who
currently have limited treatment options. Genprex works with
world-class institutions and collaborators to in-license and
develop drug candidates to further its pipeline of gene therapies
in order to provide novel treatment approaches. The Company’s lead
product candidate, Oncoprex™, is being evaluated as a treatment for
non-small cell lung cancer (NSCLC). Oncoprex has a multimodal
mechanism of action that has been shown to interrupt cell signaling
pathways that cause replication and proliferation of cancer cells;
re-establish pathways for apoptosis, or programmed cell death, in
cancer cells; and modulate the immune response against cancer
cells. Oncoprex has also been shown to block mechanisms that create
drug resistance. In January 2020, the U.S. Food and Drug
Administration granted Fast Track Designation for Oncoprex
immunogene therapy for NSCLC in combination therapy with
osimertinib (AstraZeneca’s Tagrisso®). For more information, please
visit the Company’s web site at www.genprex.com or follow Genprex
on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding the
Company’s future growth and financial status and regarding our
commercial partnerships and intellectual property licenses. Risks
that contribute to the uncertain nature of the forward-looking
statements include the presence and level of the effect of our
product candidates, alone and in combination with other therapies,
on cancer; the timing and success of our clinical trials and
planned clinical trials of Oncoprex™, alone and in combination with
targeted therapies and/or immunotherapies, and whether our other
potential product candidates, including our gene therapy in
diabetes, advance into clinical trials; the success of our
strategic partnerships; the timing and success of obtaining FDA
approval of Oncoprex™ and our other potential product candidates
including whether we receive fast track or similar regulatory
designations; costs associated with developing our product
candidates and whether patents will ever be issued under patent
applications that are the subject of our license agreements. These
and other risks and uncertainties are described more fully under
the caption “Risk Factors” and elsewhere in our filings and reports
with the United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200608005112/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2023 to Mar 2024